Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Outlook

Thelansis’s “Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Overview

Advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFR-mutated NSCLC) is a molecularly defined lung adenocarcinoma subtype driven by activating EGFR mutations, most commonly exon 19 deletions and exon 21 L858R substitutions, constitutively activating downstream RAS-MAPK and PI3K-AKT proliferative signalling. Representing approximately 10-15% of NSCLC in Western populations and significantly higher in East Asian populations, it predominantly affects never-smoker or light-smoker patients, frequently presenting with advanced stage disease and central nervous system metastases. EGFR mutation detection via next-generation sequencing is mandatory at diagnosis, encompassing common and uncommon mutations alongside co-mutation profiling informing prognosis and therapeutic selection. Osimertinib, a third-generation EGFR inhibitor with robust CNS penetration, remains a highly utilised frontline standard; however, the combination of amivantamab plus lazertinib, including a recently approved convenient subcutaneous formulation, has fundamentally redefined frontline standards by delivering superior progression-free survival over osimertinib monotherapy in the MARIPOSA trial, establishing combination therapy as the premier 2026 frontline benchmark for eligible patients. Osimertinib plus chemotherapy addresses patients requiring rapid tumour burden reduction. Acquired resistance mechanisms including EGFR C797S mutation, MET amplification, and histological transformation mandate comprehensive liquid or tissue biopsy re-profiling at progression. Patritumab deruxtecan development has been discontinued following Phase III failure, leaving emerging fourth-generation EGFR inhibitors and combination strategies as active investigational priorities. Prognosis is markedly favourable compared to unselected NSCLC; multidisciplinary molecular tumour board evaluation, CNS surveillance, and patient-centred long-term monitoring are integral to optimising outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)